Dear Colleagues,

Since its introduction in the late 1980s, the widespread use of PSA had led to overdiagnosis and to an increase in unnecessary biopsies, which has ultimately lead to overtreatment of low-risk prostate cancer. For bladder cancer and renal cell carcinoma, there are no specific diagnostic, prognostic, or predictive biomarkers. Testis cancer is generally silenced at an early stage, leading to loss of the opportunity for early diagnosis and treatment. Notably, the identification of noninvasive biomarkers will provide useful tools for personalized medicine. Unfortunately, currently used biomarkers for urological cancers are far from ideal, lacking specificity and sensitivity. Many candidate molecules that act as potential biomarkers for clinical management of patients with prostate, bladder, testis, and renal cancers have been proposed.

Thus, the content of the Special Issue will focus on general approaches that will contribute to identifying noninvasive biomarkers useful for diagnosis, prognosis, and follow-up of patients with urological cancers.
Original research articles and full reviews are welcome.

On behalf of the Diagnostics, you are warmly invited to contribute an article to the Special Issue “Tumor Markers in Urological Cancers: Current Advances and Future Perspectives.

Prof. Daniela Terracciano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Prostate cancer
• PSA
• bladder cancer
• renal cancer
• biomarkers
• testis cancer
• endocrine-related cancer
• non-coding RNA
• metabolomics
• tumor markers
• tumor inflammation